Cagrilintide is a long-acting synthetic analog of human amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. It is being developed by Novo Nordisk both as a standalone agent and in fixed-dose combination with semaglutide (CagriSema). The CagriSema combination targets complementary appetite pathways — amylin acts on hindbrain satiety circuits while GLP-1 acts on hypothalamic and gut pathways. In the REDEFINE Phase 3 program, CagriSema achieved 20.4% weight loss at 68 weeks. Novo Nordisk filed for FDA approval in 2026.
Category: Metabolic / Amylin Analog. Evidence rating: B (meaningful human data).
Clinical status: Phase 3 (REDEFINE program). NDA filed with FDA in 2026 for CagriSema.
Cagrilintide activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and other hindbrain regions, promoting meal-related satiety through distinct pathways from GLP-1 agonism. It slows gastric emptying, suppresses inappropriate glucagon release, and activates central…
Research base: 42 registered clinical trials and 42 indexed publications reference Cagrilintide.
Safety considerations: GI adverse events: 79.6% in CagriSema group vs 39.9% placebo (nausea, vomiting, diarrhea, constipation); GI events mainly transient and mild-to-moderate; Similar safety profile to GLP-1 class: pancreatitis risk, gallbladder events, thyroid C-cell tumors in rodents.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-07-05.
Related peptides: Pramlintide.
Compare: Cagrilintide vs Pramlintide.
CagriSema is a fixed-dose combination of cagrilintide 2.4 mg (amylin analog) and semaglutide 2.4 mg (GLP-1 agonist) administered as a single once-weekly injection. It targets two complementary appetite pathways, producing greater weight loss than either component alone. Novo Nordisk filed for FDA approval in 2026.
CagriSema (amylin + GLP-1) and tirzepatide (GIP + GLP-1) target different complementary pathways to GLP-1. CagriSema achieved ~20.4% weight loss at 68 weeks. Tirzepatide achieved ~22.5% at 72 weeks (SURMOUNT-1). Head-to-head data is not yet available. The two represent competing next-generation obesity therapeutics.
Cagrilintide is a long-acting amylin analog researched for weight management. It works differently from GLP-1 agonists and is often studied in combination with other peptides.
CAGRILINTIDE has been studied for: Appetite regulation, Weight management research, Glycemic control. Amylin analog; often researched in combination protocols.
Amylin receptor agonist that may influence satiety signaling, slow gastric emptying, and reduce glucagon secretion.